Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:10:04 2024-12-04 am EST			5-day change	1st Jan Change
10.56 ^USD	+20.08%		+19.80%	-7.04%

Nov. 15	Altimmune Reports 'Significant' Drop in Inflammatory Lipids With Pemvidutide in Liver Disease Treatment	MT
Nov. 15	Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024	CI

Altimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024

November 12, 2024 at 07:09 am EST

Altimmune, Inc. reported earnings results for the third quarter and nine months ended September 30, 2024. For the third quarter, the company reported sales was USD 0.005 million compared to USD 0.362 million a year ago. Sales was USD 0.005 million compared to USD 0.362 million a year ago. Net loss was USD 22.85 million compared to USD 20.67 million a year ago. Net loss was USD 22.85 million compared to USD 20.67 million a year ago. Basic loss per share from continuing operations was USD 0.32 compared to USD 0.39 a year ago. Basic loss per share from continuing operations was USD 0.32 compared to USD 0.39 a year ago.
For the nine months, sales was USD 0.015 million compared to USD 0.389 million a year ago. Sales was USD 0.015 million compared to USD 0.389 million a year ago. Net loss was USD 71.88 million compared to USD 56.81 million a year ago. Net loss was USD 71.88 million compared to USD 56.81 million a year ago. Basic loss per share from continuing operations was USD 1.01 compared to USD 1.1 a year ago. Basic loss per share from continuing operations was USD 1.01 compared to USD 1.1 a year ago.

Latest news about Altimmune, Inc.

Altimmune Reports 'Significant' Drop in Inflammatory Lipids With Pemvidutide in Liver Disease Treatment	Nov. 15	MT
Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024	Nov. 15	CI
Altimmune, Inc. Presents at UBS Global Healthcare Conference 2024, Nov-13-2024 09:30 AM	Nov. 13
Altimmune, Inc., Q3 2024 Earnings Call, Nov 12, 2024	Nov. 12
Earnings Flash (ALT) ALTIMMUNE Reports Q3 Revenue $5,000	Nov. 12	MT
UBS Initiates Altimmune at Buy With $26 Price Target	Nov. 12	MT
Altimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 12	CI
Altimmune Names Greg Weaver Chief Financial Officer	Nov. 11	MT
Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer	Nov. 11	CI
Altimmune, Inc. Announces Successful Completion of End-of-Phase 2 Meeting with FDS for Pemvidutide in the Treatment of Obesity	Nov. 07	CI
Altimmune Completes Enrollment for Phase 2b Trial of Pemvidutide in Chronic Liver Disease	Sep. 30	MT
Altimmune, Inc. Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis	Sep. 30	CI
Sector Update: Health Care Stocks Advance Late Afternoon	Sep. 10	MT
Altimmune Shares Jump After Pemvidutide Shows Strong Lean Mass Preservation in Obesity Trial	Sep. 10	MT
Altimmune, Inc. Announces That David J. Drutz Will Not Stand for Re-Election to the Board	Aug. 15	CI
Altimmune, Inc., Q2 2024 Earnings Call, Aug 08, 2024	Aug. 08
Earnings Flash (ALT) ALTIMMUNE Reports Q2 Revenue $5,000	Aug. 08	MT
Earnings Flash (ALT) ALTIMMUNE Reports Q2 Loss $-0.35 Per Share, vs. Street Est of Loss $-0.35 Per Share	Aug. 08	MT
Altimmune, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Aug. 08	CI
Altimmune, Inc. Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease in Journal of Hepatology	Jul. 25	CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell 3000 Growth Index	Jun. 30	CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell Microcap Growth Index	Jun. 30	CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell 3000E Growth Index	Jun. 30	CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell 2000 Growth Index	Jun. 30	CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell 2500 Growth Index	Jun. 30	CI

Chart Altimmune, Inc.

Duration

Period

ALT: Dynamic Chart

Company Profile

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Employees

Sector

Biotechnology & Medical Research

Calendar

03:30pm - Piper Sandler Healthcare Conference

More about the company